Literature DB >> 22202329

[A response to erlotinib hydrochloride in the case of post-operative recurrent thymoma].

Eisuke Takahashi1, Haruya Koshiishi, Masayoshi Takahashi.   

Abstract

A 43-year-old female was diagnosed with a recurrence of thymoma 6 years after the operation. Eight kinds of systemic chemotherapy were undergone for over 6 years. As the 9th chemotherapy, erlotinib hydrochloride was prescribed and the tumor decreased in size about 8 weeks later.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202329

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

1.  Successful Use of Erlotinib in Treating Recurrent Thymic Carcinoma: A Case Report.

Authors:  Lisa A Brown
Journal:  World J Oncol       Date:  2013-09-27

Review 2.  [Research status of molecular targeted therapy in thymic epithelial tumors].

Authors:  Lizhu Chen; Kailiang Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2014-06-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.